Sunday, June 26, 2022
HomeChildren's HealthSyrinx Bioanalytics Acquired by Synexa Life Sciences

Syrinx Bioanalytics Acquired by Synexa Life Sciences


Synexa Life Sciences BV, a worldwide chief in specialist biomarker and bioanalysis analysis providers, has in the present day introduced that it has acquired Syrinx Bioanalytics, a bioanalytical CRO based mostly in Turku, Finland. 

Picture Credit score: bogdanhoda/Shutterstock.com

The transfer is a part of Synexa’s ongoing ‘purchase and construct’ progress technique, geared toward constructing the worldwide market chief in specialist biomarker and bioanalytical providers. The 2 corporations’ service choices are very complementary, permitting the mixed group to supply shoppers a broader vary of providers, deeper scientific experience, a wider set of analytical platforms, larger capability, and an expanded geographical footprint.

Syrinx is especially robust in PK/immunogenicity bioanalysis, whereas Synexa’s core strengths lie in its broad portfolio of specialist biomarker and bioanalytical assays, spanning DNA, RNA, protein, cell, and tissue capabilities. 

Synexa is rising quickly and has nearly doubled in dimension over the past two years. As we speak is a big milestone as we proceed to ship on our purchase and construct technique with the intention of constructing a worldwide chief in specialist biomarker and bioanalytical providers. I’m excited to welcome the Syrinx leaders and co-founders, Dr. Sari Liitti and Dr. Timo Piironen, to our management group and stay up for working with them to combine our organisations easily over the approaching months.

Emile Lens, CEO of Synexa Life Sciences

The mixed group presents deep experience in biomarker and bioanalytical technique, assay improvement and validation, and medical execution throughout all phases to supply beneficial insights on new drug efficiency to shoppers within the pharma, biotech, and biosimilar sectors. The Finnish lab additional extends Synexa’s international lab community, including to current labs in Berlin, London, Cape City, and the corporate’s newly established facility in Rockville, Maryland.

Each corporations function to the best scientific, high quality, regulatory, and shopper service requirements – including to Synexa’s network-wide GCLP accreditation, the Syrinx lab brings GLP, GCP, and GMP accreditation and authorized radiopharmaceutical laboratory standing. .

Paul O’Riordan, Chairman of Synexa Life Sciences, commented: “We’re delighted to welcome the Syrinx staff to the Synexa group and are excited by the alternatives it will deliver for our workers and different stakeholders. Particularly, we anticipate the enlargement of our scientific capabilities and capability to have a really constructive influence for our biopharma shoppers, lots of whom are growing superior therapies within the areas equivalent to immunology, immuno-oncology, infectious ailments and focused radiobiologicals.”

“Synexa and Syrinx are very comparable corporations in philosophy: they each have laboratory providers based mostly on robust scientific experience and shut relationships with prospects. The businesses complement one another very nicely, with just about no overlapping capabilities. Syrinx’s providers can now be supplied to a bigger buyer base by means of Synexa; and reciprocally, we’re in a position to supply Synexa’s providers to our current prospects. New alternatives will open up for the personnel within the worldwide setting, and we anticipate that operations in Turku will develop considerably within the subsequent few years” acknowledged Dr. Sari Liitti, CEO of Syrinx Bioanalytics.

RELATED ARTICLES

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Recent Comments